Drug profile · INN
mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10)
SIILTIBCY
mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10) (SIILTIBCY) is an FDA-listed pharmaceutical active ingredient.
EMA: approved Various (V04) V04CF
Patents linked 0
Pipeline programs 32
News articles 0
Drug details — mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10)
- Class
- Various (V04)
- Route
- —
- Patents
- 0
- Programs
- 32
- Data quality
- 0.83
Quick answer
mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10) (SIILTIBCY) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10)
Brand SIILTIBCY
Therapeutic class Various (V04)
ATC code V04CF
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10)?
mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10) (SIILTIBCY) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10)?
SIILTIBCY is a marketed brand name for mycobacterium tuberculosis derived antigens (rdesat-6 / rcfp-10). Check FDA Drugs@FDA for the current US label holder and prescribing information.